SecBot SecBot
8-K ·Filed Jul 31, 2026

KPTI

Karyopharm Therapeutics Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001193125-26-326995
8-K context-dependent: Items 8.01
Actionable Insight ◆ Mixed

Monitor the sNDA submission for selinexor in myelofibrosis in August 2026 and any FDA feedback; a positive outcome could be a major catalyst. Also watch for announcements regarding financing or strategic alternatives, which could lead to dilution or a sale of the company.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.92
T+0 close · Jul 31, 2026 · via day close
Latest settled
−74.89%
T+60 · $0.4821
Vs SPY
−77.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $1.92entry
  2. T+1 · 4mo ago +2.60%α +1.18% · $1.97
  3. T+5 · 3mo ago +10.42%α +6.91% · $2.12
  4. T+20 · 3mo ago −2.60%α −5.59% · $1.87
  5. T+60 · 22d ago −74.89%α −77.35% · $0.4821
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm announced Phase 3 XPORT-EC-042 trial failure for selinexor in endometrial cancer (PFS p=0.0791, not significant), while simultaneously disclosing plans to submit an sNDA for selinexor in myelofibrosis in August 2026 under accelerated approval, though the FDA has requested further discussion on supporting data. The company is also exploring financing and strategic alternatives with Centerview Partners to extend its cash runway, signaling financial pressure.

Key Facts

  • Phase 3 XPORT-EC-042 trial of selinexor in TP53 wild-type endometrial cancer failed to meet primary endpoint of PFS (HR=0.76, p=0.0791, not statistically significant)
  • Company plans to submit sNDA for selinexor + ruxolitinib in myelofibrosis in August 2026 under accelerated approval pathway
  • FDA provided written feedback that SVR35 qualifies as a surrogate endpoint but requires further discussion on data to support sNDA and conversion to traditional approval
  • Company exploring financing transactions and strategic alternatives with Centerview Partners to extend cash runway; no assurance of any transaction
  • Trial results do not affect ongoing trials of selinexor in other indications

Financial Impact

No financial figures provided in the filing; the failed trial removes a potential revenue stream, while the myelofibrosis sNDA represents a key pipeline catalyst. Cash runway concerns are highlighted by the strategic alternatives exploration.

pipeline valuecash runway

Risk Factors

  • FDA may not accept the sNDA or may require additional data, delaying or preventing accelerated approval
  • Failed endometrial cancer trial reduces pipeline optionality and may impair investor confidence
  • Company may need to raise capital on dilutive terms or fail to secure financing, increasing going-concern risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-326995
Document: 0001193125-26-326995-index-headers.html0001193125-26-326995
Document: 0001193125-26-326995-index.html0001193125-26-326995
Document: 0001193125-26-326995.txt0001193125-26-326995

US Market Status

Market Closed · Opens in 7h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 31, 2026